Jaguar Health provides crofelemer on compassionate-use basis for infant with intestinal failure due to congenital sodium diarrhea

Clinical results were already presented in June 2026 from ongoing pediatric investigations in microvillus inclusion disease, short bowel syndrome with intestinal failure.

Those studies indicated patients reduced reliance on parenteral support over long-term dosing, with tolerability described as favorable.

A randomized double-blind phase in a pivotal pediatric microvillus inclusion disease trial has been completed, with data expected to support regulatory discussions.

An NDA filing for crofelemer in microvillus inclusion disease is targeted for mid-2027, with a potential Breakthrough Therapy request beforehand.

Jaguar Health expanded compassionate-use access to its oral crofelemer formulation for an infant with intestinal failure linked to congenital sodium diarrhea.